Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
06 août 2018 13h00 HE
|
Nohla Therapeutics
SEATTLE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
31 juil. 2018 08h30 HE
|
ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
29 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
HighQ featured in Sunday Times’ Lloyds SME Export Track 100
27 févr. 2018 14h19 HE
|
HighQ
LONDON, Feb. 27, 2018 (GLOBE NEWSWIRE) -- HighQ has again earned distinction in Fast Track’s Sunday Times Lloyds SME Export Track 100, which tracks Britain’s small- and medium-sized private...
ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
08 janv. 2018 08h30 HE
|
ARCA biopharma, Inc.
-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
16 août 2017 08h30 HE
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 WESTMINSTER,...
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
01 juin 2017 09h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
31 mai 2017 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates ProQR receives Fast Track designation by the U.S. Food and Drug Administration (FDA). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients...
ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update
15 mai 2017 08h30 HE
|
ARCA Biopharma, Inc.
WESTMINSTER, Colo., May 15, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP
06 juil. 2016 08h00 HE
|
Clinuvel Pharmaceuticals Limited
FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPPNDA filing allowed on a rolling basisFDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment ...